|Announcement Title||Change - Announcement of Cessation|
|Date & Time of Broadcast||Sep 10, 2021 22:00|
|Announcement Sub Title||CESSATION OF CHIEF FINANCIAL OFFICER|
|Submitted By (Co./ Ind. Name)||Mr. Yet Kum Meng|
|Designation||Chief Executive Officer and Executive Director|
|Description (Please provide a detailed description of the event in the box below)||Cessation of Chief Financial Officer.
This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.
The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, firstname.lastname@example.org.
|Name Of Person||Yik Yen Shan, Vincent|
|Is effective date of cessation known?||Yes|
|If yes, please provide the date||30/11/2021|
|Detailed Reason (s) for cessation||Mr. Yik Yen Shan, Vincent ("Mr. Yik") had, on 9 September 2021, tendered his resignation as Chief Financial Officer of OUE Lippo Healthcare Limited (the "Company" and together with its subsidiaries, the "Group"), to pursue other career opportunities. Mr. Yik will be serving his notice period pursuant to his service contract with the Company and his last day of service with the Company will be 30 November 2021.
After having interviewed Mr. Yik and to the best of its knowledge, the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd., is satisfied that save as disclosed in this announcement, there are no other material reasons for the cessation of Mr. Yik as the Chief Financial Officer of the Company.
In addition, there are no concerns with regards to financial reporting that led to the cessation of Mr. Yik as the Chief Financial Officer and there are no disagreements between Mr. Yik and the Board of Directors (the "Board") of the Company with regards to practices that would have an impact to the Company's and/or the Group's financial reporting.
The Company is in the process of finding a suitable replacement for the position of Chief Financial Officer, and will make the necessary announcement when a suitable candidate is appointed.
The Board would like to extend its gratitude and appreciation to Mr. Yik for his invaluable contributions to the Company during his tenure of service.
|Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?||No|
|Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?||No|
|Any other relevant information to be provided to shareholders of the listed issuer?||No|
|Date of Appointment to current position||01/07/2019|
|Does the AC have a minimum of 3 members (taking into account this cessation)?||Yes|
|Number of Independent Directors currently resident in Singapore (taking into account this cessation)||2|
|Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months||0|
|Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)||Chief Financial Officer|
|Role and responsibilities||Responsible for the Group's overall financial and management accounting, treasury, taxation, investment management and other corporate matters.|
|Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries||Nil.|
|Shareholding interest in the listed issuer and its subsidiaries?||No|
|Past (for the last 5 years)||Refer to Appendix A|
|Present||Refer to Appendix B|